Lishunfu (Afatinib) 40mg Tablets | Acebright China Generic | GLT

Generic Information: Lishunfu (Afatinib) — Acebright, China

Lishunfu is a domestic Chinese generic of afatinib produced by Shanghai Acebright Pharmaceuticals Co., Ltd., a subsidiary of the Acebright group specializing in oncology generics. Supplied as 40 mg film-coated tablets in a 7-tablet strip, Lishunfu delivers the standard-dose, second-generation irreversible EGFR inhibitor in a compact weekly format at a highly affordable price. As a consistency-evaluated generic, it provides a cost-effective pathway to EGFR-targeted therapy for patients with EGFR-mutant non-small cell lung cancer.

What Is Lishunfu (Afatinib) Used For?

Lishunfu is used to treat locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations, including exon 19 deletions, the L858R substitution, and uncommon mutations such as G719X, L861Q and S768I. It is a first-line therapy for EGFR-mutant NSCLC and is also used in metastatic squamous NSCLC after progression on platinum-based chemotherapy.

How Does Lishunfu (Afatinib) Work?

Lishunfu contains afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor that covalently binds EGFR, HER2 and ErbB4. This permanent blockade shuts down the signaling pathways that EGFR-mutant lung cancer cells rely on for growth and survival, delivering durable tumor control and activity against uncommon EGFR mutations.

Indications

Lishunfu is indicated for adults with locally advanced or metastatic non-small cell lung cancer whose tumors have non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing after platinum-based therapy. EGFR mutation testing is required before starting treatment.

Dosage

The recommended dose is 40 mg once daily, taken at least one hour before or two hours after a meal. The 7-tablet strip is one week of therapy at the standard dose. A 30 mg dose may be used for severe renal impairment or to manage tolerability, under oncologist supervision.

Side Effects

Common side effects of Lishunfu include diarrhea, acneiform rash, stomatitis, paronychia, dry skin and decreased appetite. Serious adverse reactions such as interstitial lung disease, hepatotoxicity and severe skin disorders are uncommon but require prompt medical attention. Proactive management of diarrhea and skin symptoms supports adherence.

Storage

Store Lishunfu in a cool, dry place away from sunlight and moisture, in its original packaging. Keep out of reach of children and swallow tablets whole with water.

Why Choose the GLT?

Lishunfu through GLT offers Acebright's consistency-evaluated afatinib generic in a practical weekly strip, at a price that makes long-term EGFR-targeted therapy accessible. As a Hong Kong-licensed supplier, we source genuine stock and provide the documentation needed for confident purchasing. For patients seeking an affordable, quality-assured 40 mg afatinib, Lishunfu is a dependable option.

How to Order Lishunfu (Afatinib)

To order, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. Share your quantity and destination, and we will confirm availability, pricing and delivery.

FAQ

Who makes Lishunfu? Lishunfu is produced by Shanghai Acebright Pharmaceuticals Co., Ltd., a Chinese generic oncology manufacturer.

What strength is available? This listing covers the 40 mg, 7-tablet strip, which is one week of standard once-daily therapy.

Is Lishunfu equivalent to the originator? Yes, Lishunfu passed the national consistency evaluation, confirming bioequivalence to the originator afatinib.

Do I need a prescription? Yes, afatinib is a prescription oncology medicine used under physician supervision.